Abiopharma

TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) Announces Clinical Trial Update TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) provided an update on its clinical development programs. Clinical Development Highlights: Clinical development progress update.

• targeting BTLA offers opportunities for cancer immunotherapy and has the potential to demonstrate additive or synergistic activity when combined with other checkpoint antagonists, potentially overcoming resistance mechanisms and improving clinical outcomes. The Company studied TNX-4700
• targeting BTLA offers opportunities for cancer immunotherapy and has the potential to demonstrate additive or synergistic activity when combined with other checkpoint antagonists, potentially overcoming resistance mechanisms and improving clinical outcomes. The Company studied four potent, high affinity, human/cyno cross-reactive, human antagonistic anti-BTLA monoclonal antibodies. Three antagonists had reduced FcgRI binding and no binding to FcgRIIB compared to an antibody control, which the Company believes has the potential to improve pharmacokinetics and confer a reduced risk of FcR-dependent adverse events, such as cytokine release syndrome or other immune-mediated toxicities. The second poster presentation, entitled Pharmacokinetics of TNX-1700